News Press release

SeqOne Genomics appoints Martin Dubuc, Senior Pharmaceutical and Digital Health Executive to its Board of Directors

Welcome Martin Dubuc to the SeqOne Genomics board

M. Dubuc will strengthen the Board’s capabilities in the fields of personalized medicine and companion diagnostics

Montpellier, France – Thursday, 26th of October, 2024 – SeqOne Genomics, a French company specialized in artificial intelligence-enhanced genomic analysis solutions, is pleased to announce the appointment of Martin Dubuc to its board of directors.

SeqOne Genomics is at the forefront of genomic data analysis in clinical applications, pioneering innovative software solutions that leverage artificial intelligence enabling more precise and personalized medicine.

Mr. Martin Dubuc, is a seasoned senior executive with Global experience who most recently headed up Biogen’s Global Digital Health division driving personalized and digital medicine. He brings over two decades of experience in the pharmaceutical industry at Pfizer, Merck&Co and Biogen across France, Europe and US combined with thought leadership expertise in digital health.

Sacha Loiseau, Ph.D., chairperson of SeqOne Genomics’ Board, stated: “I am thrilled to welcome Martin Dubuc to SeqOne’s Board. His deep insights into the pharmaceutical industry, combined with his knowledge of digital health technologies, will be
instrumental in taking SeqOne Genomics to the next level and providing the most advanced genomic analysis solutions for the pharmaceutical industry.”

“I was immediately seduced by the combination of people, hard science and technical
expertise underlying SeqOne’s genomic analysis platform, coupled with their focus on developing in-vitro diagnostics and companion diagnostics making personalized medicine a reality for patients and bringing innovative capabilities as a strategic
partner to LifeScience companies across the lifecycle.” commented Mr. Dubuc, “The exponential and converging progress of technologies underlying genomic testing opens a new era of opportunities. SeqOne is well positioned to make a meaningful
difference for patients partnering with LifeScience companies catalyzing precision medicine therapy development, genetic disease diagnosis, personalized medicine, and companion diagnostics”.

Dr. Nicolas Philippe, CEO and co-founder of SeqOne Genomics, concluded: “Martin Dubuc is a very strong addition to our Board of Directors. Martin’s shrewd business acumen and knowledge of the pharmaceutical industry have already proven to add significant value and will continue to help us as we strengthen our pharma offering and expand internationally.”

About SeqOne Genomics:
SeqOne Genomics offers high-performance genomic analysis solutions for healthcare
providers, treating patients suffering from cancer, rare and hereditary diseases as well
as pharmaceutical companies developing new therapies. The solution supports both
short read and long-read nanopore sequencing and leverages advanced machine
learning coupled with the company’s proprietary genomics platform to dramatically
reduce turnaround times and costs while delivering comprehensive and actionable
insights for personalized medicine. The company has won numerous awards including
the iLab award and the ARC cancer foundation’s Hélène Stark prize and has twice been
nominated for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital
Investissement, Merieux Equity Partners, Omnes and Software Club.


Jean-Marc HOLDER
+33 (0) 9 54 40 42 84

Published on 26 October 2023

Need help improving your genomic analysis process ?
We'd love to help !